Cencora (NYSE:COR – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.
Risk and Volatility
Cencora has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Profitability
This table compares Cencora and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cencora | 0.79% | 125.45% | 4.18% |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cencora | $321.33 billion | 0.20 | $1.55 billion | $13.46 | 24.56 |
| Mangoceuticals | $460,000.00 | 19.27 | -$20.64 million | ($1.01) | -0.41 |
Cencora has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
97.5% of Cencora shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 0.4% of Cencora shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Cencora and Mangoceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cencora | 0 | 3 | 13 | 0 | 2.81 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Cencora currently has a consensus target price of $370.85, indicating a potential upside of 12.20%. Given Cencora’s stronger consensus rating and higher possible upside, equities analysts clearly believe Cencora is more favorable than Mangoceuticals.
Summary
Cencora beats Mangoceuticals on 11 of the 14 factors compared between the two stocks.
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
